Hudson Susan Claire has made a notable stock acquisition in Flowserve Corp, acquiring 31 shares at a price of $80.35 each. This transaction, filed on November 2, 2026, is significant as it reflects the confidence of the Chief Legal Officer in the company’s future performance. Such moves can influence not only the company but also the broader pumps and pumping equipment industry.
Background
Hudson Susan Claire is identified as an officer at Flowserve Corp, a company operating in the pumps and pumping equipment sector. The company is listed under the Central Index Key 0000030625. Flowserve Corp is incorporated in New York and has its fiscal year ending on December 31. Recent filings indicate ongoing activity, with multiple Form 4 submissions highlighting stock transactions by its officers.
What the Filing Says
The recent filing indicates that Hudson Susan Claire acquired 31 shares of Flowserve Corp common stock on November 2, 2026. Following this transaction, Claire holds a total of 24,953 shares. The filing notes that these shares were acquired under the non-qualified Flowserve Corporation 2024 Employee Stock Purchase Plan, indicating a structured approach to employee stock ownership.
Impact
This acquisition may have implications for Flowserve Corp's employee engagement and retention strategies, as it reflects a commitment from its officers to invest in the company’s stock. Such actions can foster a culture of ownership and align the interests of management with those of shareholders. The transaction may also influence the perception of Flowserve Corp within the pumps and pumping equipment industry, potentially impacting its competitive standing.
What's Next
The filing does not say what happens next.
Read Next
Smith Byron Jr. Acquires 1,160 Shares of Northern Trust Corp
Etsy CFO Charles Baker Reports Stock Transactions
Catalyst Acquisition Corp. Updates Beneficial Ownership Stakes
Hampton Financial Corp Raises Governance Concerns Over Icon Energy
HCA Healthcare Executive Reports Multiple Stock Transactions
LENZ Therapeutics updates beneficial ownership in SEC filing









